Fibrogen Investor Alert: Class Action Lawsuit Filed

Boston, Massachusetts – (Newsfile Corp. – April 22, 2021) – Thornton law firm advises investors that a class action lawsuit has been filed on behalf of investors by FibroGen, Inc. (NASDAQ: FGEN). The case is currently in the lead plaintiff stage. Investors who purchased FGEN shares or other securities between November 8, 2019 and April 6, 2021 can contact Thornton’s investor protection team at www.tenlaw.com/cases/FibroGen to submit their information . Investors can also email investors@tenlaw.com or call 617-531-3917.

More information: www.tenlaw.com/cases/FibroGen

In the case, it is alleged that FibroGen and its officers have made misleading statements to investors and have failed to disclose: (i) FibroGen’s prior disclosure of primary cardiovascular safety research in the United States from the Roxadustat Phase 3 program for the treatment of certain anemia Safety assessments submitted in connection with CKD included post-hoc changes in stratification factors; (ii) FibroGens analyzes with the specified stratification factors lead to higher hazard rates (point estimates of the relative risk) and 95% confidence intervals; (iii) Based on these analyzes, FibroGen was unable to conclude that Roxadustat reduced (or superior to) the risk of MACE + on dialysis and of MACE and MACE + on dialysis compared to epoetin-alfa. and (iv) as a result, FibroGen faced significant uncertainty that its NDA for roxadustat for the treatment of CKD anemia would be approved by the FDA.

Interested FibroGen investors have until June 11, 2021 to seek advice and apply as the lead plaintiff if they are interested. Investors do not have to be a lead plaintiff to be a class member. A lead plaintiff is acting on behalf of all other members of the investor class in administering the class action. If investors fail to take action, they can remain an absent class member. The class has not yet been certified. Investors will not be represented by a lawyer until certification.

The story goes on

More information: www.tenlaw.com/cases/FibroGen

Thornton’s securities attorneys have extensive experience representing investors in recovering damages caused by violations of securities laws. The company’s attorneys have a proven record of litigation in securities cases in courts across the country and recovering losses on behalf of investors. This can be seen as a lawyer promotion in some countries. Past results do not guarantee or forecast a similar result with respect to future matters.

CONTACT:

Law firm Thornton LLP
1 Lincoln Street
State Street Financial Center
Boston, MA 02111
www.tenlaw.com/cases/FibroGen

The source version of this press release can be found at https://www.newsfilecorp.com/release/81408

Comments are closed.